4D Molecular Therapeutics Files 8-K
Ticker: FDMT · Form: 8-K · Filed: Oct 31, 2025 · CIK: 1650648
| Field | Detail |
|---|---|
| Company | 4d Molecular Therapeutics, INC. (FDMT) |
| Form Type | 8-K |
| Filed Date | Oct 31, 2025 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.0001, $85 million, $50 million, $335.5 million |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, 8-k
TL;DR
4D Molecular Therapeutics just signed a big deal, filing an 8-K on 10/31/25.
AI Summary
On October 31, 2025, 4D Molecular Therapeutics, Inc. filed an 8-K report. The filing indicates an entry into a material definitive agreement. Specific details of the agreement, including parties involved and financial terms, are not provided in this excerpt.
Why It Matters
This filing signals a significant new contract or partnership for 4D Molecular Therapeutics, which could impact its future operations and financial performance.
Risk Assessment
Risk Level: medium — The filing indicates a material definitive agreement, which could carry significant implications, but the lack of specific details makes the exact risk level uncertain.
Key Players & Entities
- 4D Molecular Therapeutics, Inc. (company) — Registrant
- October 31, 2025 (date) — Date of Report
- Delaware (jurisdiction) — State of Incorporation
- 5858 Horton Street #455 (address) — Principal Executive Offices
- Emeryville, California (location) — Principal Executive Offices Location
FAQ
What type of material definitive agreement did 4D Molecular Therapeutics enter into?
The filing states that 4D Molecular Therapeutics, Inc. entered into a material definitive agreement, but the specific nature of the agreement is not detailed in this excerpt.
When was this material definitive agreement entered into?
The report indicates that the earliest event reported, which includes the entry into the material definitive agreement, occurred on October 31, 2025.
What is the principal executive office address for 4D Molecular Therapeutics, Inc.?
The principal executive offices of 4D Molecular Therapeutics, Inc. are located at 5858 Horton Street #455, Emeryville, California, 94608.
What is the IRS Employer Identification Number for 4D Molecular Therapeutics, Inc.?
The IRS Employer Identification Number for 4D Molecular Therapeutics, Inc. is 47-3506994.
What is the SIC code for 4D Molecular Therapeutics, Inc.?
The Standard Industrial Classification (SIC) code for 4D Molecular Therapeutics, Inc. is 2836, which corresponds to Biological Products (No Diagnostic Substances).
Filing Stats: 952 words · 4 min read · ~3 pages · Grade level 15.3 · Accepted 2025-10-31 06:02:29
Key Financial Figures
- $0.0001 — ange on which registered Common Stock, $0.0001 par value per share FDMT Nasdaq Glo
- $85 million — d to provide an upfront cash payment of $85 million and expected cost sharing of at least $
- $50 million — n and expected cost sharing of at least $50 million dollars over the next three years for g
- $335.5 million — tion, the Company is eligible for up to $335.5 million in potential regulatory and commercial
Filing Documents
- d41653d8k.htm (8-K) — 27KB
- 0001193125-25-259302.txt ( ) — 139KB
- fdmt-20251031.xsd (EX-101.SCH) — 3KB
- fdmt-20251031_lab.xml (EX-101.LAB) — 18KB
- fdmt-20251031_pre.xml (EX-101.PRE) — 11KB
- d41653d8k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. 4D MOLECULAR THERAPEUTICS, INC. Date: October 31, 2025 By: /s/ David Kirn David Kirn, M.D. Chief Executive Officer